News
GYRE
6.34
-2.76%
-0.18
Weekly Report: what happened at GYRE last week (0706-0710)?
Weekly Report · 18h ago
Weekly Report: what happened at GYRE last week (0629-0703)?
Weekly Report · 07/06 09:10
Weekly Report: what happened at GYRE last week (0622-0626)?
Weekly Report · 06/29 09:09
Gyre Therapeutics files to sell 30.22M shares of common stock for holders
TipRanks · 06/23 10:06
Top Gyre Therapeutics Executive Makes Surprise Stock Move
TipRanks · 06/23 02:03
Gyre Therapeutics COO Ye Weiguo disposes of USD 87,450 common shares
PUBT · 06/22 20:03
Weekly Report: what happened at GYRE last week (0615-0619)?
Weekly Report · 06/22 09:10
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
TipRanks · 06/16 12:01
Gyre Therapeutics shareholders elect directors at annual meeting
PUBT · 06/16 10:31
Top Executive Makes Notable Move With Gyre Therapeutics Stock
TipRanks · 06/16 02:10
Gyre COO Weiguo Ye disposes of 2,800 common shares for $17,276
PUBT · 06/15 20:01
Weekly Report: what happened at GYRE last week (0608-0612)?
Weekly Report · 06/15 09:10
Top Gyre Therapeutics Insider Quietly Cashes Out in a Major Stock Move
TipRanks · 06/12 02:03
Gyre Therapeutics COO Ye Weiguo sells USD 129,295 of common shares
PUBT · 06/11 20:01
Top Executive’s Bold Move at Gyre Therapeutics Stirs Investor Buzz
TipRanks · 06/09 02:10
Gyre Therapeutics COO Ye Weiguo disposes of USD 217,732 of common shares
PUBT · 06/08 20:02
Weekly Report: what happened at GYRE last week (0601-0605)?
Weekly Report · 06/08 09:10
Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy
TipRanks · 06/02 10:32
Gyre Therapeutics publishes corporate presentation on fibrosis, inflammatory disease and cancer pipeline
PUBT · 06/02 00:07
Weekly Report: what happened at GYRE last week (0525-0529)?
Weekly Report · 06/01 09:10
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.